地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：18372041646
邮箱：sales@amyjet.com
Demeditec 公司成立于1987年，位于德国，是一家体外诊断试剂专业供应商。其产品包括各种RIA, ELISA, PCR检测试剂盒，可以检测血液，血清，血浆，尿液样本，2006年，Demeditec研发出了使用唾液样本即可成功检测游离激素的ELISA检测试剂盒。Demeditec产品涵盖了内分泌学，骨代谢，肾脏学，神经递质，肿瘤标记物，自身免疫，传染病等各个领域。
Demeditec Diagnostics is a supplier for diagnostic testkits to be used in the clinical laboratory and in research labs as well. The technology of our testkits covers radioactive (RIAs) and non-radioactive (ELISA, rapid tests) origin.
Most of our testkits are designed to be used for samples like blood, serum, plasma, and urine. Since 2006 we also are offering saliva tests in ELISA format for the measurement of free steroids and other salivary analytes. Demeditec Diagnostics is certified according to ISO 9001 and ISO 13485.
主要产品领域包括：
Allergy
Autoimmunity
Biogenic Amines
Bone Metabolism
Diabetes
Down-Syndrome
Food Analytics/Safety
Food Intolerance
Growth Factor
Hematology
Immunology
Infectious Disease
Nephrology
Rapid Tests
Reproduction
Salivary Diagnostics
Specialities
Thyroid
Thyroid Antibodies
Tumormarker
Veterinary Diagnostics
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Demeditec"> Demeditec
E&K Scientific公司成立于1975年，是生物技术和制药研究实验室提供实验试剂和仪器设备的主要供应商，有着超过40年的经验。
At E&K Scientific our mission is to excel in the distribution of life science research supplies by offering an unparalleled customer experience centered on technical expertise, innovation, and personalized service.
E&K offers almost 50 years of experience as a premier provider of laboratory supplies and instrumentation to the Academic, Biotech, and Pharmaceutical Research Laboratories. The company was founded in 1975 by Egon and Kay Ruf and their son, Brian Ruf, took over as President and CEO in 2000.
E&K Scientific公司的主要产品包括：
Biological Buffers
Blotting & Electrophoresis
Cell Culture
Chromatography Supplies
DNA/RNA Purification
Equipment & Instruments
Filtration & Separation
Gloves & Apparel
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="E&K Scientific"> E&K Scientific
艾美捷科技特约代理Ellastin Products Company公司产品。Ellastin Products Company成立30余年，产品不多但是获得了许多客户的青睐，这些客户遍布于高校，研究机构，医学中心等。
Elastin Products Company, Inc. has been manufacturing quality biochemicals for 30 years. Providing research products to many pharmaceutical companies, universities, and researchers. Our quality in products have been estabilished for many years through the publishing of papers using EPC as the source. Thank you for the continued interest in our products.
ELASTIN PRODUCTS COMPANY的主要产品包括：
Polyclonal Antibody to Human Lung Tryptase IgG purified
Polyclonal Antibody to Proteinase 3-IgG purified
Polyclonal Antibody to Porcine Pancreas Elastase
Polyclonal Antibody to Human Myeloperoxidase
Monoclonal Antibody to Bovine Ligamentum Nuchae Elastin
Human Sputum Leucocyte Myeloperoxidase
Elastin Soluble
Lipase
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Elastin Products Company"> Elastin Products Company
Zedira是一家临床阶段的生物技术公司，专门从事转谷氨酰胺酶的研究，开发一系列小分子药物候选物。Zedira公司正致力于药物发现的前沿领域，该领域涉及阻止调节失调的转谷氨酰胺酶的小分子。此外，Zedira是一个全球品牌，专门用于转谷氨酰胺酶领域的研发和诊断试剂，其独特和高质量的产品有助于推动转谷氨酰胺酶的研究和应用。
Zedira is a clinical stage biotech company specialised in transglutaminase. Zedira conducts its own development of small molecular drug candidates. In doing so, the company is working at the cutting edge of drug discovery involving small molecules that block dysregulated transglutaminases. In addition, Zedira is a global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. Numerous unique and high quality products help pushing forward transglutaminase-related science – both in academia and industry.
Zedira公司主要产品：
Transglutaminases
Microbial Transglutaminase
Assays and Substrates
Inhibitors
Antibodies and Microarrays
Proteases
Protein Labeling
Blood Coagulation
Cereal Proteins
Celiac Disease Products
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
Zedira产品详情请咨询我司客服人员：
| 产品编号 | 产品名称 | 产品规格 |
| A003 | Polyclonal antibody to human tissue transglutaminase (TG2) | 100 ug |
| A004 | Monoclonal antibody to tissue transglutaminase (TG2) | 100 ug |
| A008 | Polyclonal antibody to human transglutaminase 5 (TG5) | 500 ug |
| A011 | Monoclonal antibody to gliadin (clone XGY1) | 1 mg |
| A013 | Monoclonal antibody to gliadin (clone XGY7) | 1 mg |
| A014 | Polyclonal antibody to human tissue transglutaminase (TG2) | 500 ug |
| A015 | Polyclonal antibody to human epidermal transglutaminase (TG3) | 500 ug |
| A016 | Polyclonal antibody to human blood coagulation factor XIII (A-subunit) | 500 ug |
| A017 | Polyclonal antibody to human neuronal transglutaminase (TG6) | 500 ug |
| A018 | Polyclonal antibody to human keratinocyte transglutaminase (TGI) | 500 ug |
| A020 | Polyclonal antibody to microbial protransglutaminase (pro-MTG, pro-BTG) | 500 ug |
| A021 | Polyclonal antibody to human plasminogen (rhPLG) | 500 ug |
| A022 | Polyclonal antibody to human prostate transglutaminase (TG4) | 500 ug |
| A023 | Monoclonal antibody to N'-ly-L-glutamylpL-lysine-isopeptide bond | 100 ug |
| A024 | Monoclonal Antibody to microbial (bacterial) Transglutaminase | 100 ug |
| A028 | FITC-labeled polyclonal antibody to human TG2 | 200 ug |
| A029 | FITC-labeled polyclonal antibody to human TGI | 200 ug |
| A030 | FITC-labeled polyclonal antibody to human TG3 | 200 ug |
| A031 | FITC-labeled polyclonal antibody to human TG6 | 200 ug |
| A032 | FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 ug |
| A033 | Monoclonal antibody to human TG2 (Catalytic Domain, clone XTG17) | 200 ug |
| A034 | Monoclonal antibody to human TG2 (Beta Sheet Domain, clone XTG 1 1) | 200 ug |
| A035 | Monoclonal antibodies to gliadin (Set No 1) | 1 Set |
| A036 | Monoclonal antibody to human TG2 (Beta Barrel 1 Domain, clone XTG21) | 200 ug |
| A037 | Monoclonal antibody to human TG2 (Beta Barrel 2 Domain, clone XTG1 8) | 200 ug |
| A040 | Polyclonal antibody to human transglutaminase 7 (TG7) | 200 ug |
| A042 | Monoclonal antibody to human TGI (clone XTG3 1) | 200 ug |
| A044 | FITC-labeled polyclonal antibody to human TG5 | 200 ug |
| A046 | D-Dimer monoclonal mouse antibody, clone 3B6 | 100 ug |
| A047 | D-Dimer monoclonal mouse antibody, clone 1 D2 | 100 ug |
| A051 | Biotinylated polyclonal antibody to microbial transglutaminase (MTG) | 50 ug |
| A052 | Biotinylated polyclonal antibody to human factor XIII (A-subunit) | 50 ug |
| A053 | Biotinylated polyclonal antibody to human TG2 | 50 ug |
| A054 | Monoclonal antibody to gliadin (clone XGY6) | 1 mg |
| A057 | Monoclonal antibody to deamidated gliadin | 100 ug |
| A058 | Monoclonal antibody to gliadin (clone XGY5) | 1 mg |
| A059 | Monoclonal antibody to gliadin (clone XGY9) | 1 mg |
| A060 | Monoclonal antibody to gliadin (clone XGY10) | 1 mg |
| A061 | Monoclonal antibody to gliadin (clone XGY 1 6) | 1 mg |
| A062 | Monoclonal antibody to deamidated and non-deamidated gliadin | 100 ug |
| A063 | Monoclonal antibody to gliadin (clone XGY2) | 1 mg |
| A064 | Monoclonal antibody to gliadin (clone XGY4) | 1 mg |
| A065 | Monoclonal antibody to gliadin (clone XGY8) | 1 mg |
| A066 | Monoclonal antibody to gliadin (clone XGY 1 2) | 1 mg |
| A067 | Monoclonal antibody to gliadin (clone XGY 1 5) | 1 mg |
| A068 | Monoclonal antibody to gliadin (clone XGY 1 7) | 1 mg |
| A069 | Monoclonal antibody to gliadin (clone XGY23) | 1 mg |
| A070 | Monoclonal antibody to gliadin (clone XGY24) | 1 mg |
| A071 | Monoclonal antibody to hordein (clone XH4) | 1 mg |
| A072 | polyclonal antibody to mouse tissue Transglutaminse | 200 ug |
| A074 | Polyclonal antibody to human blood coagulation factor XIII (B-subunit) | 200 ug |
| A075 | FITC-labeled polyclonal antibody to mouse TG2 | 200 ug |
| A076 | DD-XLink-mab | 100 ug |
| A077 | FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 ug |
| A078 | Polyclonal antibody to human epidermal transglutaminase (TG3) Protein A | 250 ug |
| A079 | Biotin-DD-XLink-mab | 50 ug |
| A082 | Monoclonal antibody to human TG3 (clone XTG45) | 200 ug |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg |
| A102 | TG2-Assay Substance. Abz-APE(CAD-DNP)QEA-OH | 10 mg |
| A105 | NQEQVSPLTLLK, alpha2-Antiplasmin peptide (1-12) | 25 mg |
| A106 | (ATTO-48 8TM)cadaveri ne | 1 mg |
| A108 | Ac-(D)-Asp-MA-N le-Nle-Leu-Pro-Trp-Pro-OH | 5 mg |
| A109 | β-Amyloid peptide 1-42 (Aβ 1-42) | 1 mg |
| A112 | (ATTO-532)cadaverine | 1 mg |
| A113 | (ATTO-550)cadaverine | 1 mg |
| A114 | (AnO-647N)cadaverine | 1 mg |
| A115 | (ATTO-700)cadaverme | 1 mg |
| A125 | Factor XIII activation peptide | 10 mg |
| A132 | Ac-WALQRPHYSYPD | 10 mg |
| A139 | Monoclonal antibody to human TG6 (Catalytic Domain, clone XTG52) | 200 ug |
| A140 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG39) | 200 ug |
| A141 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG68) | 200 ug |
| A142 | Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG57) | 200 ug |
| A143 | Monoclonal antibody to microbial Transglutaminase (clone XM67) | 200 ug |
| A144 | Monoclonal antibody to microbial Transglutaminase (clone XM68) | 200 ug |
| A145 | Polyclonal Antibody to microbial Transglutaminase | 200 ug |
| A152 | 3-Azido-l -propanamine | 100 mg |
| A153 | 4-Azidobutan-l-amine | 100 mg |
| A154 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) | 200 ug |
| A155 | Monoclonal antibody to human factor XIII (Catalytic Domain, clone XTG02) | 200 ug |
| B001 | Biotinyl-Thr-Val-GIn-GIn-Glu-Leu-OH | 5 mg 25 mg |
| B002 | N-(Biotinyl)cadaverine | 25 mg 100 mg |
| B003 | Boc-DON-Gln-lle-Val-OMez "Boc-DON” | 10 mg |
| B006 | Thr-Val-Gln-Gln-Glu-Leu-OH | 25 mg |
| B007 | Keratinocyte transglutaminase (TGI )-substrate-peptide K5 | 10 mg |
| B008 | Tissue transglutaminase (TG2)-substrate-peptide T26 | 10 mg |
| B009 | Epidermal transglutaminase (TG3)-substrate-peptide E51 | 10 mg |
| B010 | Blood coagulation FXIII-substrate-peptide Fl 1 KA | 10 mg |
| B013 | Neuronal transglutaminase (TG6)-substrate peptide Y25 | 10 mg |
| B014 | Transglutaminase 7 (TG7)-substrate peptide Z3S | 10 mg |
| B015 | Biotin-Ahx-MA-QPL-OMe | 10 mg |
| B017 | Microbial Transglutaminase (MTG)-substrate peptide M48 | 10 mg |
| B019 | Biotin-Ahx-QVPL-OMe | 10 mg |
| C001 | Z-GIn-Gly-OH | 1g |
| C002 | Z-GIn-Gly-CAD-DNS | 25 mg 100 mg |
| C074 | Z-Gln-Gly-CAD-(AnO-488) | 1 mg |
| C075 | Z-Gln-Gly-CAD-(ATTO-532) | 1 mg |
| C076 | Z-Gln-Gly-CAD-(AnO-550) | 1 mg |
| C077 | Z-Gln-Gly-CAD-(ATTO-647N) | 1 mg |
| C078 | Z-Gln-Gly-CAD-(AnO-700) | 1 mg |
| C079 | Z-GIn-Gly-PEG(3)-N3 | 25 mg |
| C080 | Z-Gln-Gly-PEG(11)-N3 | 25 mg |
| C090 | Z-GIn-Gly-CAD-TAMRA | 25 mg |
| C091 | Z-GIn-Gly-CAD-Biotin | 25 mg |
| C092 | Z-Gln-Gly-(PEG1,088), monodisperse | 25 mg |
| C093 | Z-Gln-Gly-(PEG5,000), polydisperse | 25 mg |
| C094 | Tosyl-ε-aminopentyl-CMK | 1 mg |
| C095 | Dansyl-ε-aminopentyl-CMK | 1 mg |
| C102 | MTG Blocker | 10 mg 25 mg |
| D001 | Dansyl-ε-aminohexanoyl-GIn-GIn-lle-Val-OH | 25 mg 100 mg |
| D002 | N-(2,4-Dinitrophenyl)cadaverine | 100 mg |
| D003 | 1,3-Dimethyl-2[(2-oxo-propyl)thio]imidazolium chloride | 100 mg |
| D004 | 1,3-Dimelhyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium | 10 mg |
| D005 | Metalloprotease-Assay-Substance, DABCYL-Ser-Phe-EDANS | 2 mg |
| D006 | N-(Dansyl)cadaverine | 100 mg |
| D007 | Cadaverine | 100 mg |
| D008 | "DALP", DNP-aminohexanoic acid-Lys-aminopropanol | 5 mg |
| D009 | DALP-methyl carbamate | 5 mg |
| D0I 6 | LDN 27219 | 10 mg |
| E018 | ZediXclusive Tissue Transglutaminase EIA | 1 Kit |
| E021 | ZediXclusive Microbial Transglutaminase (MTG) ELISA | 1 Kit |
| E103 | ZediXclusive TG6-ab ELISA (IgA) | 1 Kit (96 wells) |
| E104 | ZediXclusive TG6-ab ELISA (IgG) | 1 Kit (96 wells) |
| F001 | FXIII-Assay Kit | 1 Kit |
| F002 | Tissue Transglutaminase Assay Kit | 1 Kit |
| F004 | Fibrinogen, purified from human plasma | 50 mg |
| F006 | FITC-labeled Fibrinogen | 5 mg |
| F007 | Fibrin Glue (porcine) | 1 Kit |
| F008 | Fibrin Glue (bovine) | 1 Kit |
| F011 | Cross-linked fibrin degradation products, xFDPs | 200 ug |
| F012 | Fibrin degradation products, FDPs | 200 ug |
| G001 | Alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G002 | Deamidated alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G003 | Ac-PLQPEQPFPK(ε-Biotin), Deamidated gliodin peptide | 10 mg |
| G004 | Ac-PEQLPQFEEK(ε-Biotin), Deamidated gliadin peptide | 10 mg |
| G005 | DGPx4 (Fusion protein of 4 deamidated gliadin peptides) | 500 ug |
| G006 | DGPx2 (Fusion protein of 2 deamidated gliadin peptides) | 500 ug |
| G007 | DGPxl (deamidated gliadin peptide) | 500 ug |
| G008 | Omega-5 gliadin | 500 ug |
| G009 | Alpha2-gliadin, 33mer (aa 56-88) | 5 mg |
| G011 | Deamidated alpha2-gliadin, 33mer, (Acetyl-aa56-88-amide, Q65E) | 5 mg |
| G013 | QPFPQPQLPYPQPQ-amide | 10 mg |
| G014 | QPFPQPELPYPQPQ-amide | 10 mg |
| G017 | Biotinylated DGPx1 | 100 ug |
| G018 | Barley albumin and globulin | 5 mg |
| G019 | Barley prolamin (Hordein) | 5 mg |
| G020 | Barley glutelin (Hordenin) | 5 mg |
| G021 | Rye albumin and globulin | 5 mg |
| G022 | Rye prolamin (Secalin) | 5 mg |
| G023 | Rye glutelin (Secalinin) | 5 mg |
| G024 | Corn albumin and globulin | 5 mg |
| G025 | Corn prolamin (Zein) | 5 mg |
| G026 | Corn glutelin (Zeanin) | 5 mg |
| G027 | Rice albumin and globulin | 5 mg |
| G028 | Rice prolamin (Oryzin) | 5 mg |
| G029 | Rice glutelin (Oryzenin) | 5 mg |
| G030 | Spell albumin and globulin | 5 mg |
| G031 | Spelt prolamin | 5 mg |
| G032 | Spelt glutelin | 5 mg |
| G033 | Oat albumin and globulin | 5 mg |
| G034 | Oat prolamin (Avenin) | 5 mg |
| G035 | Oat glutelin (Avenalin) | 5 mg |
| G036 | Wheat albumin and globulin (Leukosin and Edestin) | 5 mg |
| G037 | Wheat prolamin (Gliadin) | 5 mg |
| G038 | Wheat glutelin (Glutenin) | 5 mg |
| G039 | Durum wheat albumin and globulin | 5 mg |
| G040 | Durum wheat prolamin | 5 mg |
| G041 | Durum wheat glutelin | 5 mg |
| G042 | Soy protein, saline soluble fraction | 5 mg |
| G043 | Soy protein, ethanol soluble fraction | 5 mg |
| G044 | Soy protein, propanol/urea/DTE soluble fraction | 5 mg |
| G045 | Millet (Sorghum) albumin and globulin | 5 mg |
| G046 | Millet (Sorghum) prolamin (Kafirin) | 5 mg |
| G047 | Millet (Sorghum) glutelin | 5 mg |
| G048 | L-Glutamic acid γ-monohydroxamate | 100 mg |
| G051 | 26mer gliadin peptide | 250 ug |
| G052 | 33mer gliadin peptide | 250 ug |
| G054 | 33mer DGP | 250 ug |
| G055 | Carrier protein control | 250 ug |
| G056 | DGP and Gliadin peptides (Set No 1) | 1 Set |
| G057 | Alpha2-gliadin, 33mer (aa56-88), TAMRA labeled | 5 mg |
| G058 | Alpha2-gliadin, 33mer (aa56-88), TAMRA and Biotin labeled | 5 mg |
| G101 | Gly-Pro-Arg-Pro-amide | 25 mg |
| I001 | Involucrme, recombinant human | 500 ug |
| K004 | "KxD", Boc-Lys-en-DNS | 10 mg |
| L001 | Substrate Finder Kit | 1 Kit |
| L101 | Biotin TGase Protein Q-Labeling Kit | 1 Kit |
| L102 | PEG1,088 TGase Protein Q-Labeling Kit | 1 Kit |
| L103 | PEG5,000 TGase Protein Q-Labeling Kit | 1 kit |
| L104 | ATTO-488™ TGase Protein Q-Labeling Kit | 1 Kit |
| L105 | ATTO-532™ TGase Protein Q-Labeling Kit | 1 Kit |
| L106 | ATTO-550™ TGase Protein Q-Labeling Kit | 1 Kit |
| L107 | ATTO-647N™ TGase Protein Q-Labeling Kit | 1 Kit |
| L108 | ATTO-700™ TGase Protein Q-Labeling Kit | 1 Kit |
| L201 | Biotin TGase Protein K-Labeling Kit | 1 Kit |
| L202 | PEG1,088 TGase Protein K-Labeling Kit | 1 Kit |
| L203 | PEG5,000 TGase Protein K-Labeling Kit | 1 Kit |
| L204 | ATTO-488™ TGase Protein K-Labeling Kit | 1 Kit |
| L205 | ATTO-532™ TGase Protein K-Labeling Kit | 1 Kit |
| L206 | ATTO-550™ TGase Protein K-Labeling Kit | 1 Kit |
| L207 | ATTO-647N™ TGase Protein K-Labeling Kit | 1 Kit |
| L208 | ATTO-700™ TGase Protein K-Labeling Kit | 1 Kit |
| M001 | MTG-ANiTA-Kit | 1 Kit |
| M003 | Tissue Transglutaminase Pico-Assay Kit | 1 Kit |
| P003 | Prolylendopeptidase from Myxococcus xanthus, recombinant | 150U |
| P004 | PT-Gluten | 1 mg 10 mg |
| P009 | human Pro-Glu-Plasminogen, recombinant | 100 ug |
| P010 | (PEG1,088)amine, monodisperse | 10 mg |
| P011 | (PEG5,000)amine, polydisperse | 10 mg |
| P012 | human Plasmin, recombinant | 100 ug |
| P0U | Urokinase | 1 mg |
| P015 | Streptokinase (bacterial plasminogen activator) | 1 mg |
| P016 | Tissue Plasminogen Activator | 100 ug |
| P111 | PEPperCHIP Pan-Transglutaminase Microarray | 1 Chip |
| P112 | PEPperCHIP Custom Transglutaminase Microarray | 1 Chip |
| P113 | PEPperCHIP Transglutaminase Microarray Service | 1 Sample |
| P114 | PepSlide Analyzer | 3-Month/1-Year/Perpetual License |
| P115 | PEPperCHIP Incubation Tray 3/1 | 1 Tray |
| P116 | PEPperCHIP Staining Kit | 1 Kit |
| P117 | PEPperCHIP Transglutaminase 2 Microarray | 1 Chip |
| P118 | PEPperCHIP Incubation Tray 3/5 | 1 Tray |
| R001 | N-(Tetrametylrhodaminyl)cadaverine | 10 mg |
| R002 | TAMRA-DON | 5 mg 10 mg |
| T001 | Microbial (bacterial) transglutaminase | 25 U; 1 x 250 U;10x 25 U; lx 500 U; 20x 25 U |
| T002 | Human tissue transglutaminase (TG2) | 250 ug 1mg |
| T004 | N-(p-Tosyl)-Gly-Pro-Lys-pNA | 25 mg |
| T006 | Guinea pig liver transglutaminase | 10U |
| T009 | Human keratinocyte transglutaminase (TG1) | 150 ug |
| T011 | Human transglutaminase 7 | 250 ug |
| T013 | Human epidermal transglutaminase, Dispose activated | 200 ug |
| T016 | Microbial (bacterial) Pro-transglutaminase | 250 ug |
| T018 | Inactive human tissue transglutaminase | 250 ug 1 mg |
| T021 | Human neuronal transglutaminase (TG6) | 250 ug |
| T022 | Human tissue transglutaminase (TG2) | 250 ug 1 mg |
| T024 | Human epidermal transglutaminase (TG3) | 200 ug |
| T027 | Human blood coagulation Factor Xlll-A z recombinant | 200 ug |
| T034 | Human tissue transglutaminase (TG2) | 100 ug |
| T035 | Human keratinocyte transglutaminase (TGI) | 150 ug |
| T036 | Transglutaminase Assay Kit, fluorescent, Casein, Dansylcadaverine | 1 Kit |
| T038 | Rat tissue transglutaminase | 250 ug 1 mg |
| T039 | Guinea pig liver transglutaminase, recombinant | 10U |
| T040 | Mouse tissue transglutaminase | 250 ug 1 mg |
| T042 | Human prostate Transglutaminase (TG4) | 100 ug |
| T050 | Human blood coagulation Factor XIII B subunit | 200 ug |
| T051 | Open tTG™ | 250 ug |
| T055 | Tissue Transglutaminase Microassay Kit, colorimetric | 1 Kit |
| T056 | Human alpha thrombin, highly active | 200 U |
| T057 | Inhibited human epidermal transglutaminase | 250 ug |
| T061 | Mouse blood coagulation Factor Xlll-A2 | 200 ug |
| T062 | Dog blood coagulation Factor Xlll-A2 | 200 ug |
| T063 | Human blood coagulation Factor Xlll-A2 , Val34Leu-mutant | 200 ug |
| T064 | Inhibited human neuronal transglutaminase | 250 ug |
| T065 | Rat blood coagulation Factor Xlll-A2 | 200 ug |
| T066 | Pig blood coagulation Factor Xlll-A2 | 200 ug |
| T067 | Human tissue transglutaminase (TG2), endotoxin free | 250 ug 1 mg |
| T070 | Human Factor Xllla, Thrombin activated | 200 ug |
| T072 | Dog tissue transglutaminase | 250 ug 1 mg |
| T086 | Human Transglutaminase 5 | 100 ug |
| T087 | Tridegin | 200 ug |
| T092 | Human blood coagulation Factor Xlll-A2 | 100 ug |
| T101 | 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg |
| T102 | Mouse Open TG2 | 250 ug 1 mg |
| T106 | Biotinylated human tissue transglutaminase (TG2) | 100 ug 250 ug |
| T108 | Cynomolgus tissue transglutaminase | 250 ug |
| T109 | Cynomolgus open TG2 | 100 ug |
| T1 10 | Recombinant TG2 [E.coli] | 500 ug |
| T1 14 | Blood Coagulation Factor Xlll-Microassay Kit, colorimetric | 1 Kit |
| T117 | Biotinylated inactive hTG2 (Cys277Ser) | 250 ug 1 mg |
| T122 | Recombinant TG2 (insect cells) | 500 ug |
| T123 | Biotinylated human tissue transglutaminase (TG2) | 50 ug |
| T124 | Recombinant TG3 (insect cells) | 400 ug |
| T127 | Biotinylated human blood coagulation Factor XIII | 50 ug |
| T134 | Open tTG™ | 100 ug |
| T139 | Rabbit tissue transglutaminase | 250 ug 1mg |
| T140 | Biotinylated human epidermal transglutaminase | 100 ug |
| T141 | Biotinylated human neuronal transglutaminase | 100 ug |
| T142 | Biotinylated mouse blood coagulation Factor Xlll-A2 | 50 ug |
| T146 | Mouse neuronal transglutaminase | 250 ug |
| T148 | Biotinylated human Open tTG™ | 50 ug 1 mg |
| T149 | Oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T150 | Biotinylated mouse open TG2 | 50 ug |
| T151 | Biotinylated oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T152 | Rabbit blood coagulation Factor Xlll-A2 | 200 ug |
| T153 | Microbial (bacterial) transglutaminase, edotoxin free | 25 U;10x 25 U;20x 25 U |
| T156 | Biotinylated mouse tissue transglutaminase | 250 ug; 1 mg |
| T159 | Pig tissue transglutaminase | 250 ug; 1 mg |
| T160 | Biotinylated cynomolgus tissue transglutaminase | 50 ug |
| T161 | Cynomolgus blood coagulation Factor Xlll-A2 | 200 ug |
| T167 | Short human tissue transglutaminase, aa 1-475 | 250 ug |
| T168 | Human tissue transglutaminase, C23OA mutant | 250 ug;1 mg |
| T169 | Human tissue transglutaminase, R580A mutant | 250 ug;1 mg |
| T173 | Human tissue transglutaminase, R116C mutant | 1 mg |
| T178 | Microbial transglutaminase with C-terminal His6-tag | 25 U;10 x 25 U;20 x 25 U |
| T184 | Cat tissue transglutaminase | 200 ug |
| T187 | Factor XIII activation peptide, recombinant | 500 ug |
| T197 | Coagulation factor XIII, recombinant human Factor Xlll-A2 | 100E;250E |
| T222 | Human alpha Thrombin, recombinant | 100 NIH Units |
| Z004 | Z-Gln-GIn-Pro-Leu-OH | 25 mg |
| Z006 | Z-DON-Val-Pro-Leu-OMe,"Z-DON" | 10 mg |
| Z009 | ZediXclusive Microbial Transglutaminase Assay Kit | 1 Kit |
| Z010 | ZediXclusive Tissue Transglutaminase Assay Kit | 1 Kit |
| Z011 | Z-(D)-DON-Val-Pro-Leu-OMe | 10 mg |
| Z013 | Z-MA-QPL-OMe | 10 mg |
| Z015 | Keillor inhibitor AA9 | 10 mg |
| Z016 | Keillor inhibitor NC9 | 10 mg |
| Z017 | Keillor inhibitor VA4 | 10 mg |
艾美捷科技代理STEMCELL Technologies品牌。
STEMCELL Technologies为世界各地从事干细胞、免疫学、癌症、再生医学和细胞治疗研究的科学家提供高质量的细胞培养基、细胞分离技术、仪器和配套产品。
STEMCELL Technologies特色产品包括：
（1）EasySep™ 总核酸提取试剂盒：磁性总核酸（DNA 和 RNA）提取试剂盒
（2）CellAdhere™ Laminin-521：与 TeSR™ 维持培养基结合用于维持人 ES 和 iPS 细胞的基质
（3）EasySep™ 人骨髓 CD138 阳性选择试剂盒 (IVD)：从骨髓中免疫磁性阳性选择人 CD138+ 细胞用于体外诊断 (IVD) 应用的样品
（4）GyneCult™ 输卵管类器官培养基：无血清和性类固醇模块化试剂盒，用于人类输卵管类器官的扩增和分化
< " data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理STEMCELL Technologies品牌"> 艾美捷科技代理STEMCELL Technologies品牌
艾美捷科技提供Biomol品牌产品。
Biomol是一家德国综合性的生命科学产品供应商，目前有来自40个品牌的52万余种产品。
With a growing portfolio of 520,000 products from more than 40 suppliers, Biomol has been connecting researchers with products to support their discoveries for over 50 years. We combine our understanding of life science research with a curated collection of products from specialized manufacturers to meet the needs of researchers.
Biomol的主要产品包括：
Antibodies
Assays
Biological Samples
Chemicals
Cytokines
Kits
Plasmids
Primers
Proteins & Peptides
Accessory Reagents
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Biomol"> Biomol
艾乐美生物科技有限公司（AllerMAbs Co., Ltd.）成立于2015年，是台湾一家专注于生产高亲和力、高纯度并具有过敏原特异性的嵌合人类IgE单克隆抗体的生物公司。公司创办人团队在科研过程中发现市面上缺乏多样的IgE单克隆抗体，特別是具有过敏原特异性的人IgE 单抗。如果能制备出这种抗体，将有助于IgE 相关领域的研究工作。因此，AllerMAbs公司团队开始思考与研究利用基因克隆动物来制造人类 IgE 抗体的可行性，经过数年的努力于 2014年开发出人类IgE 抗体基因嵌入小鼠，通过杂交瘤技术 (Hybridoma technology)，成功地研制出分泌嵌合人类IgE 单抗的 IgE 杂交瘤与纯化 IgE 抗体。经测试，此种嵌合人类IgE 单抗的物化性质与对免疫细胞的活性，皆与人类IgE 抗体一致，研究成果于2015 年发表在国际学术期刊上。
AllerMAbs的产品解决了目前人类IgE抗体不易制备的问题，让嵌合人类IgE抗体可以成为人类IgE抗体的替代品，并提供一个更稳定、更符合血清IgE检测系统的校正品，让临床血清IgE的检测结果更加准确与可靠。
其利用动物基因转殖技术，将组成人类IgE抗体分子的ε重链(Heavy chain)和κ轻链(Light chain)的编码基因(Encoding genes)，分別嵌入(Knock-in)小鼠胚胎干细胞(Embryonic stem cells, ES cells)的γ1重链和κ轻链基因的位置，接着把胚胎干细胞分別植入孕母鼠体内，并将其带有嵌入基因之成鼠交互配种，最后得到带有人类IgE抗体重链和轻链基因的基因嵌入小鼠(HεκKI mice)，且体内能制造完整的嵌合人类IgE抗体分子。
技术优势
容易制备IgE杂交瘤与IgE单抗
过敏原特异性
良好的亲和力与专一性
高纯度与高稳定性
可结合至嗜碱性粒细胞上的IgE受体与刺激細胞
可大量生产与高浓度制备
非人类血液来源(相较于血清IgE抗体)
适合用作检测用的校正品
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="AllerMAbs"> AllerMAbshttp://www.amyjet.com/Index/lists/catid/99/kid/56.html
| 产品名称 | 规格 |
| Ammonia/Iron Standard Kit (Verichem Laboratories; CAT#9040) | 5x15mL |
| Ammonia/Iron Standard Level F (Verichem Laboratories; CAT#9046) | 1x15mL |
| Bilirubin Standard Kit (Verichem Laboratories; CAT#9450) | 10x5mL |
| Bilirubin Standard, Level F (Verichem Laboratories; CAT#9436) | 2x5mL |
| Tru-Zero™ Bilirubin Standard (Verichem Laboratories; CAT#9456) | 2x5mL |
| Br2 Bilirubin Calibrator (Verichem Laboratories; CAT#9459) | 2x5mL |
| Carbon Dioxide Standard Kit (Verichem Laboratories; CAT#9210) | 5x15mL |
| Carbon Dioxide Standard, Level F (Verichem Laboratories; CAT#9216) | 1x15mL |
| Electrolyte Standard Kit (Verichem Laboratories; CAT#9200) | 5x15mL |
| Enzyme Er™ Verifier Kit (Verichem Laboratories; CAT#9410) | 6x5mL |
| Enzyme Er™ Verifier, Level G (Verichem Laboratories; CAT#9417) | 1x5mL |
| Ethanol Standard Kit (Verichem Laboratories; CAT#9670) | 6x5mL |
| Hdl Cholesterol Verifier Kit (Verichem Laboratories; CAT#9560) | 6x5mL |
| Matrix Plus™ Chemistry Reference Kit (Verichem Laboratories; CAT#9500) | 5x15mL |
| Matrix Plus™ Chemistry Reference, Level F (Verichem Laboratories; CAT#9506) | 1x15mL |
| Matrix Plus™ Cholesterol Reference Kit (Verichem Laboratories; CAT#9550) | 5x15mL |
| Matrix Plus™ Cholesterol Reference, Level F (Verichem Laboratories; CAT#9556) | 1x15mL |
| Microprotein Standard Kit (Verichem Laboratories; CAT#9480) | 5x15mL |
| Serum Ise Standard Kit (Verichem Laboratories; CAT#9240) | 5x15mL |
| Total Protein / Albumin Standard Kit (Verichem Laboratories; CAT#9460) | 5x15mL |
| Total Protein / Albumin Standard, Level F (Verichem Laboratories; CAT#9466) | 1x15mL |
| Urine Chemistry Standard Kit (Verichem Laboratories; CAT#9000) | 5x15mL |
| Urine Uric Acid Standard Kit (Verichem Laboratories; CAT#9020) | 5x5mL |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Verichem Laboratories"> Verichem Laboratories
Pantomics公司成立于2004年，产品包含组织微阵列、组织切片、组织块，此外还提供组织样本定制生产服务。Pantomics公司具有完备的产品体系，研究者可根据研究物种、解剖学结构、病理状态，选择所需要的组织样本产品。
Pantomics, Inc. is a tissue array company founded by Dr. Langxing Pan, a pathologist, in 2004. The company makes and provides animal and human tissue arrays, for use in research, routine IHC/ISH control and education. Pantomics, Inc. also utilizes its own pathology resources to conduct tissue section-based RNA/protein analyses and/or target validation services for academia and industry.
Pantomics, Inc. has aimed at producing the highest standard tissue arrays for RNA and protein analyses. To achieve this, the company has established the following:
A strong scientific advisory board consisting of individuals with extensive experience in pathology diagnostics, teaching and research.
A dedicated tissue acquisition and processing center.
A work force of well trained technicians, scientists and pathologists.
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172469628
传真：13212737804
邮箱：sales@amyjet.com
0.3478
